tbuckley/cabot-search huggingface dataset:
P3.01-76 Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number
Authors: K. Nosaki, Y. Umeyama, R. Toyozawa, S. Takamori, N. Haratake, N. Miura, T. Oba, M. Yamaguchi, T. Seto, M. Takenoyama, Y. Ichinose
Journal: Journal of Thoracic Oncology (2018)
Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)
Authors: J.L. Ramirez, A. Font Pous, J. Garcia-Donas, B. Perez Valderrama, I. Aguirre Egaña, L. Nonell, V. Ruiz de Porras Fontdevila, M. Mallo, D. Balañá, J.A. Virizuela, U. Anido, M.M. Llorente Ostiategui, M.A. Gonzalez del Alba Baamonde, N. Lainez, B. Mellado, M.A. Climent Duran, J. Bellmunt
Journal: Annals of Oncology (2018)
P1.17-10 Consolidation Chemotherapy in Stage III Non-Small Cell Lung Cancer: Still a Critical Piece of the Puzzle
Authors: P. Mohindra, M. Vyfhuis, K. Scilla, J. Feliciano, M. Edelman, W. Burrows, S. Badiyan, M. Suntharalingam, S. Feigenberg, C. Simone
Journal: Journal of Thoracic Oncology (2018)
Longitudinal association of gonorrhea and bacterial vaginosis with repeat chlamydia diagnoses among U.S. Army women: a retrospective cohort analysis
Authors: Christian T. Bautista, Eyako K. Wurapa, Warren B. Sateren, Bruce P. Hollingsworth, Jose L. Sanchez
Journal: Military Medical Research (2018)

Historically, sexually transmitted infections have affected the health of the U.S. military. To determine whether gonorrhea, bacterial vaginosis, genital herpes, and trichomoniasis are predictors of repeat chlamydia diagnoses among U.S. Army women, medical data reported into the Defense Medical Surveillance System during the 2006–2012 period were analyzed. For all inpatient and outpatient medical records, the first and second International Classification of Diseases, version 9 (ICD-9) diagnostic positions were reviewed for each chlamydia case to determine the occurrence of repeat diagnoses. The Andersen-Gill regression model, an extension of the Cox model for multiple failure-time data, was used to study associations between predictors and repeat chlamydia diagnoses. Among 28,201 women with a first chlamydia diagnosis, 5145 (18.2%), 1163 (4.1%), 267 (0.9%), and 88 (0.3%) had one, two, three, and four or more repeat diagnoses, respectively. Overall, the incidence of repeat chlamydia was 8.31 cases per 100 person-years, with a median follow-up time of 3.39 years. Gonorrhea (hazard ratio (HR) = 1.58, 95% CI: 1.44–1.73) and bacterial vaginosis (HR = 1.40, 95% CI: 1.09–1.79) were significant predictors for repeat chlamydia. These estimated hazard ratios were attenuated, but remained significant, after controlling for age, race/ethnicity, marital status, and military rank. No significant association was found for genital herpes (HR = 1.13, 95% CI: 0.55–2.29) and trichomoniasis (HR = 1.43, 95% CI: 0.43–4.68). This large cohort study suggests that gonorrhea and bacterial vaginosis were associated with repeat chlamydia diagnoses among U.S. Army women. These findings can be used in formulating new interventions to prevent repeat chlamydia diagnoses.
The functional significance of dentin sialoprotein-phosphophoryn and dentin sialoprotein
Authors: Helena Ritchie
Journal: International Journal of Oral Science (2018)

Phosphophoryn (PP) and dentin sialoprotein (DSP) are the most dominant non-collagenous proteins in dentin. PP is an extremely acidic protein that can function as a mineral nucleator for dentin mineralization. DSP was first identified in 1981, yet its functional significance is still controversial. Historically, these two proteins were considered to be independently synthesized and secreted by dental pulp cells into the developing dentin matrix. However, with the identification of the DSP coding sequence in 1994, followed 2 years later by the finding that the PP coding sequence was located immediately downstream from the DSP sequence, it became immediately clear that DSP and PP proteins were derived from a single DSP-PP (i.e., dentin sialophosphoprotein, DSPP) transcript. Since DSPP cDNA became available, tremendous progress has been made in studying DSP-PP mRNA distribution and DSP generation from the DSP-PP precursor protein at specific cleavage sites by protease tolloid-related-1 (TLR1) or bone morphogenetic protein 1 (BMP1). The functions of DSP-PP and DSP were investigated via DSP-PP knockout (KO) and DSP knockin in DSP-PP KO mice. In addition, a number of in vitro studies aimed to elucidate DSPP and DSP function in dental pulp cells.
P2.15-23 Are there Ethnic Disparities in the Clinical Outcomes of Non-Small Cell Lung Cancer Hispanic Patients Treated with Immunotherapy?
Authors: L. Raez, D. Saravia, T. Munoz-Antonia, R. Ruiz, D. Cress, A. Chiappori, B. Hunis, D. Sumarriva, H. Powery, L.A. Mas Lopez, G. Lopes, P. Izquierdo, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma
Authors: Salma Badr, Magdy Kotb, Mai Amr Elahmadawy, Hosna Moustafa
Journal: Clinical Nuclear Medicine (2018)

Purpose The aim of this study was to explore the positive predictive value and negative predictive value of FDG PET/CT. The prognostic impact of tumor burden of bone marrow infiltrates was diagnosed by FDG PET/CT at initial presentation. Methods This retrospective study enrolled 140 pediatric patients with pathologically proven lymphoma (113 Hodgkin disease and 27 Non-Hodgkin lymphoma). All patients had pretherapy FDG PET/CT. Bone marrow biopsy (BMB), clinical, radiological, and follow-up data were also collected. The skeleton was divided into 8 segments, and a 5-point scoring system was used for assessment of BM infiltration burden. Results Among the 140 lymphoma patients, FDG PET/CT revealed positive BM involvement in 41 patients; 2 of them were false-positive with negative BMB and regional MRI results. Positive predictive value was 95.1% for PET/CT compared with 100% with BMB. All patients diagnosed with positive BMI by BMB were detected by FDG PET/CT. On the contrary, BMB missed 25 patients (17.9%) with statistically significant difference. Negative predictive value was 100% for PET/CT compared with 80.2% for BMB ( P &lt; 0.05). FDG PET/CT upstaged 17.9% of the enrolled patients. Bone marrow involvement based on the 5-point scoring system was assessed. No significant difference was demonstrated in therapy outcome between patient with focal BMI (score 2) and extensive BMI (score 5; P = 0.06). Conclusions FDG PET/CT has optimum negative predictive value compared with BMB in detection of bone marrow infiltrations in pediatric lymphoma with upstaging cases missed with BMB. Prognostic impact of BMI based on the 5-point scoring system reveals that the main influence is presence or absence of BMI rather than its tumor burden.
IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
Authors: P. Schmid, S. Adams, H.S. Rugo, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Dieras, R. Hegg, S.-A. Im, G.S. Wright, V. Henschel, L. Molinero, S.Y. Chui, R. Funke, A. Husain, E.P. Winer, S. Loi, L.A. Emens
Journal: Annals of Oncology (2018)
Risk of fatigue and neuropathy in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials
Authors: V.C. Ruiz-Schutz, L.M. Gomes, C.Z. Oliveira, R.C. Mariano, D.V.P. Almeida, J.M. Pimenta, G.Z. Dal Molin, F.R. Kater, R. Yamamura, F.C. Maluf, F.A. Schutz
Journal: Annals of Oncology (2018)
P3.01-81 Long-Term Outcome of Surgically Resected Unsuspected N2 Lung Adenocarcinoma
Authors: B.J. Park, T.H. Kim, J. Lee, S. Shin, J.H. Cho, H.K. Kim, Y.S. Choi, J.I. Zo, Y.M. Shim, J. Kim
Journal: Journal of Thoracic Oncology (2018)
P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
Authors: C. Arce-Lara, E. Arriola, P. Brunsvig, E. Carcereny, M. Domine, K. Dragnev, E. Felip, R. García Campelo, M. Krebs, L. Paz-Ares, S. Ponce Aix, J. Spicer, J.M. Trigo, N. Vinolas Segarra, R. Holt, D. Micklem, A. Brown, M. Chisamore, J. Lorens
Journal: Journal of Thoracic Oncology (2018)
Changes in lung cancer incidence by sex and smoking status in China: a multicentre observational study
Authors: Yang Zhang, Difan Zheng, Huimin Li, Huibiao Zhang, Yaozeng Xie, Bin Qian, Jiaqing Xiang, Yawei Zhang, Yihua Sun, Hong Hu, Xiaoyang Luo, Ting Ye, Bin Li, Yiliang Zhang, Hang Li, Yunjian Pan, Zhendong Gao, Shanbo Zheng, Quan Liu, Shengping Wang, Yan Jin, Xuxia Shen, Fei Liang, Chen Fu, Chunxiao Wu, Fanzhen Lv, Xiaokai Huo, Kai Zhou, Ying Zheng, Yuan Li, Haiquan Chen
Journal: The Lancet (2018)
Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial
Authors: J. Kuon, F. Bozorgmehr, M.A. Schneider, J. Krisam, F. Lasitschka, M. Serke, W. Schuette, N. Moosmann, W. Gleiber, M. Faehling, M. Wermke, P. Schuett, M. Boesche, V. van Laak, L. Fischer von Weikersthal, M. Ulmer, C. Meyer zum Büschenfelde, J.R. Fischer, M. Thomas
Journal: Annals of Oncology (2018)
Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay
Authors: A. Vivancos, E. Aranda Aguilar, M. Benavides, E. Elez Fernandez, M. Toledano, M. Alvarez, E. Diaz Rubio, A. Gómez-España, V. Garcia-Barberan, M.R. Chica-Parrao
Journal: Annals of Oncology (2018)
P2.09-09 Precision and Repeatability of VENTANA DLL3 (SP347) Assay Immunohistochemistry Assay in Fine Needle Aspirations of Small Cell Lung Cancer
Authors: B. Admire, B. Holmes, E. Elgabry, C. Powell, D. Tyree, R. Marati, A. Hanlon Newell, B. Damadzadeh, D. Dalvi, R. Huang
Journal: Journal of Thoracic Oncology (2018)
Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
Authors: C. Faivre-Finn, D.R. Spigel, S. Senan, C.J. Langer, D. Raben, B. Perez, M. Özgüroğlu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, L. Paz-Ares, L. Poole, C. Wadsworth, P.A. Dennis, S.J. Antonia
Journal: Annals of Oncology (2018)
P2.01-48 Predictive Factors in NSCLC Patients with Stage IIIB/IV Treated with First Line Platinum-Doublet Chemotherapy
Authors: S. Isaksson, C. Reuterswärd, B. Hazem, H. Griph, J. Engleson, K. Ericson Lindquist, M. Planck, J. Staaf
Journal: Journal of Thoracic Oncology (2018)
P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
Authors: M. Riudavets Melià, I. Gabriela Sullivan, A. Barba Joaquín, G. Anguera Palacios, L. Del Carpio Huerta, C. Moltó Valiente, S.D. Camacho Arellano, S. Moron Asensio, P. Gomila Pons, M. Andrés Granyó, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, C. González Blanco, I. Genua Trullos, L. Tuneu Valls, N. Stantonyonge Sesnic, A. Barnadas Molins, I. Gich Saladich, M. Majem Tarruella
Journal: Journal of Thoracic Oncology (2018)
MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
Authors: H. Brown, J. Vansteenkiste, K. Nakagawa, M. Cobo Dols, T. John, C. Barker, A. Kohlmann, A. Todd, M. Saggese, J. Chmielecki, A. Markovets, S. Ramalingam
Journal: Journal of Thoracic Oncology (2018)
P1.01-14 Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis
Authors: D. Tassinari, C. Cherubini, M. Pilati, M. Papi, S.V.L. Nicoletti, L.A. Lazzari Agli, L. Landi
Journal: Journal of Thoracic Oncology (2018)
Abstract 19705: Real-time Home-to-hospital Ischemic Time Dashboard in Patients With ST segment Elevation Myocardial Infarction Results in Significant Improvement of the Logistic Chain and Lower Short-term Mortality
Authors: Maaike Hermans, Matthijs Velders, Martin Smeekes, Olivier Drexhage, Timon Ytsma, Martin Schalij, Victor Umans
Journal: Circulation (2015)

Introduction: Timely reperfusion with primary percutaneous coronary intervention (PCI) in ST segment elevation myocardial infarction (STEMI) patients is associated with superior clinical outcomes. Aiming to reduce ischemic time, an innovative system for H2H time monitoring was implemented. The objective of this study was to assess the results of a real time home-to-hospital (H2H) dashboard for monitoring and evaluation of ischemic time in STEMI patients. Methods: Ischemic time in STEMI patients transported by Emergency Medical Services (EMS) and treated with primary PCI in the Medical Center Alkmaar before (n=843) and after the implementation of the H2H dashboard (n=441) was compared. Time points in the H2H dashboard were semi-automatically registered, enabling evaluation by the EMS and Cardiology departments. Before implementation of the H2H dashboard, time points were recorded on paper and retrospectively collected. Results: Median treatment delay, first medical contact (FMC) to balloon time and door-to-balloon time were significantly shorter in the H2H group (treatment delay 142 minutes [IQR 103;221 minutes] vs. 181 minutes [IQR 134;286 minutes] P value &lt;0.001, FMC-to-balloon time 62 minutes [IQR 52;75 minutes] vs. 86 minutes [IQR 71;111 minutes] P value &lt;0.001 and door-to-balloon time 32 minutes [IQR 25;43 minutes] vs. 52 minutes [IQR 34;76 minutes] P value &lt;0.001). Adjusted for baseline characteristics, the H2H time monitoring dashboard was independently associated with shorter time delays. 90-Days survival rates were significantly higher in the H2H group, this was due to lower incidence of cardiogenic shock. Conclusions: After implementation of the H2H dashboard, significantly shorter ischemic time was observed. The use of the H2H dashboard was independently associated with shorter time delays. Short-term mortality was significantly lower in the H2H group due to lower incidence of cardiogenic shock.
P2.01-86 Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases
Authors: L. Shi, J. Tang, M. Li, L. Tong, H. Tao, W. Wu, H. Wu, L. Guo, W. Wu, H. Li, Q. Meng, L. Xu, Y. Zhu, Z. Liu
Journal: Journal of Thoracic Oncology (2018)
Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease
Authors: Erica P. Young, Nathan O. Stitziel
Journal: Annual Review of Medicine (2018)

Coronary artery disease (CAD) is a major cause of morbidity and mortality. Unfortunately, despite decades of research focused on disease pathogenesis, we still lack a sufficient pharmacopeia for preventing CAD. The failure of many novel cardiovascular drugs to improve clinical outcomes reflects the major substantial challenge of drug development: identifying causal mechanisms that can be therapeutically manipulated to lower disease risk. Identifying genetic variants that are associated with risk of CAD has emerged as a clear path toward improving our understanding of the underlying mechanisms that lead to disease and to the development of new therapies. Here, we review the potential utility and limitations of using human genetics to guide the identification of therapeutic targets for CAD.
Mutations in interferon gamma and antigen presentation pathways are frequent in hiper/ultra-mutated (HiMut) tumors and could be result of immune-editing processes in HiMut tumors
Authors: J.M. Piulats Rodriguez, S. Garcia-Mulero, L. Valle, V. Moreno, X. Matias-Guiu, R. Sanz-Pamplona
Journal: Annals of Oncology (2018)
P1.11-13 Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)
Authors: F. Wei, C. Strom, W. Liao, J. Cheng, M. Tu, D. Chia, F. Li, Y. Kim, W. Su, C. Lin, D. Elashoff, D. Wong
Journal: Journal of Thoracic Oncology (2018)
P2.17-22 Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).
Authors: N. Mohammed, P. Welsh, J. Stobo, S. Nowicki, K. Mangion, M. Sankaralingam, N. O'Rourke, M. Glegg, J. Foster, R. Woodward, J. Paul, C. Lawless, C. Berry, N. Sattar
Journal: Journal of Thoracic Oncology (2018)
Synthetic DNA immunotherapy in biochemically relapsed prostate cancer
Authors: N. Shore, E.I. Heath, L.T. Nordquist, H. Cheng, K. Bhatt, M. Morrow, T. McMullan, K. Kraynyak, J. Lee, B. Sacchetta, L. Liu, S. Rosencranz, S.T. Tagawa, L.J. Appleman, R. Tutrone, J. Garcia, Y. Whang, W. Kelly, I. Csiki, M.L. Bagarazzi
Journal: Annals of Oncology (2018)
MA10.02 Impact of Antibiotics on Outcome of Metastatic Non Small Cell Lung Cancer Patients Treated with Immunotherapy
Authors: G. Galli, M. Poggi, G. Fucà, M. Imbimbo, C. Proto, D. Signorelli, M. Vitali, N. Zilembo, M. Ganzinelli, F. De Braud, M. Garassino, G. Lo Russo
Journal: Journal of Thoracic Oncology (2018)
P1.11-08 AI Based Malignancy Prediction of Indeterminate Pulmonary Nodules: Robustness to CT Contrast Media
Authors: Q. Chometon, L. Pickup, C. Arteta, H. Peschl, S. Ather, M. Tsakok, C. Santos, P. Novotny, J. Declerck, F. Gleeson, T. Kadir
Journal: Journal of Thoracic Oncology (2018)
P1.11-06 Lung Cancer Probability in New Perifissural Nodules Detected in a Lung Cancer Screening Study
Authors: M. Heuvelmans, L. Van Smoorenburg, J. Walter, U. Yousaf-Khan, C. Van Der Aalst, M. Dorrius, M. Rook, R. Vliegenthart, H. De Koning, M. Oudkerk
Journal: Journal of Thoracic Oncology (2018)
The experience of onco-palliative care multidisciplinary meetings in Hotel Dieu de France University Hospital, an ESMO designated center of integrated oncology and palliative care
Authors: A. Houchan, T.S. Assi, Z. Bakouny, E. El Rassy, A. Tohme, M.C. Mouhawej, J.G. Kattan
Journal: Annals of Oncology (2018)

Background: Current management strategies of cancer patients are adopting multidisciplinary meetings (MDM) and including the earliest palliative care intervention to improve the quality of life and survival. We have established, since 2015, a monthly onco-palliative care MDM for the management of our cancer patients. This study reports on the role of onco-palliative MDM in Hotel Dieu de France University Hospital, an ESMO Designated Center of Integrated Oncology and Palliative Care. Methods: All cancer patients referred to the mobile palliative care unit and/or transferred to the palliative care unit, are presented and discussed during the onco-palliative care MDMs held between May 2015 and November 2017. Demographic, clinical and long-term characteristics were obtained from the electronic medical records and retrospectively nalysed. Demographic and survival data were compared between 2015 and 2017. Results: 245 patients were presented during 20 MDMs. Median age was 68 years (range 59-77) and 58% of patients were male. The most common motive for palliative care consultation was social support (40%). Over the study period, no significant effect on the place of death was retained. However, patients had significant improvement in the symptomatic management of their disease between 2015 and 2017 (41.6% vs 7% in 2015) and better social support (60.7% vs 32.4% in 2015) (p < 0.0001). The median survival of patients after the onco-palliative care MDMS was 23 days (19.3- 26.7). No significant difference in survival was noted over the 3 year course (p = 0.315). Using the univariate cox regression model, in comparison to 2015, the hazard ratio is 0.780 (0.556 – 1.094, p = 0.149) for 2016, and 0.924 (0.3652 – 1.309, p = 0.656) for 2017. Conclusions: The onco-palliative care MDMs is an innovative approach in Lebanon, a small conservative Middle Eastern society. These MDMs were shown to improve the quality of life of cancer patients with better symptomatic and social support. However, no significant impact on survival was demonstrated so far. Legal entity responsible for the study: Saint Joseph University. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis
Authors: Morten Ruhwald, Roland Diel
Journal: European Respiratory Journal (2018)

<b>The End TB Strategy calls for renewed focus on latent TB, which requires development of more predictive tests. Kik<i>et&nbsp;al.</i> provide a framework for the clinical development of such tests, an ambition that calls for joint efforts by researchers and funders.</b>http://ow.ly/O3tm30m95dy
Neurotheranostics as personalized medicines
Authors: Bhavesh D. Kevadiya, Brendan M. Ottemann, Midhun Ben Thomas, Insiya Mukadam, Saumya Nigam, JoEllyn McMillan, Santhi Gorantla, Tatiana K. Bronich, Benson Edagwa, Howard E. Gendelman
Journal: Advanced Drug Delivery Reviews (2018)

The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide "optimal" therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.
MA19.04 The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC)
Authors: Y.K. Chae, W. Park, D. Saravia, V. Florou, S. Chang, S. Wang, L. Chiec, A. Rahbari, N. Mohindra, V. Villaflor, L.C. Park, G. Lopes
Journal: Journal of Thoracic Oncology (2018)
Effect of prednisone on docetaxel pharmacokinetics in metastatic prostate cancer: A randomized drug-drug interaction study
Authors: B.P.S.I. Belderbos, K.G.A.M. Hussaarts, L. van Harten, E. Oomen-De Hoop, P. de Bruijn, P. Hamberg, R.J. van Alphen, B.C.M. Haberkorn, R.J. van Soest, R. de Wit, R.H.J. Mathijssen
Journal: Annals of Oncology (2018)
Abstract 19680: Prognostic Utility of Growth Hormone for All-Cause and Cardiovascular Mortality in a United States National Cohort of Black and White Adults
Authors: Rohit Mital, Nicholas Wettersten, Oliver Hartmann, Mary Cushman, Virginia J Howard, Gerasimos Filippatos, George Howard, Monika M Safford, Suzanne E Judd, Andreas Bergmann, Joachim Struck, Alan Maisel
Journal: Circulation (2016)

Introduction: Elevated growth hormone (GH) levels are associated with a higher incidence of cardiovascular (CV) morbidity and mortality. Despite gender differences in GH levels, the impact of gende...
OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer
Authors: J. Tsurutani, H. Park, T. Doi, S. Modi, S. Takahashi, K. Nakagawa, I. Krop, S. Waqar, K. Yoh, B. Li, S. Taira, T. Jikoh, J. Singh, M. Sugihara, P. Jänne
Journal: Journal of Thoracic Oncology (2018)
PD-L1 expression and T-cell inflamed gene expression profile (GEP) in Korean and US patients (pts) with advanced gastric cancer (GC)
Authors: S.Y. Rha, G.Y. Ku, H.S. Kim, H.C. Chung, F.G. Amlashi, D.M. Maru, C. Fein, L. Tang, M.J. Savage, W. Zhou, T. Wu, S.A. Peter, D.P. Kelsen, J.A. Ajani
Journal: Annals of Oncology (2018)
P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC
Authors: E. Felip, J. Brahmer, S. Broderick, S. Swanson, M. Awad, T. Mitsudomi, N. Girard, K. Kerr, J. Spicer, J. Cai, R. Yang, P. Forde
Journal: Journal of Thoracic Oncology (2018)